The colon is a pelvic organ too: taking the Couric challenge.
B. Karlan
DOI: https://doi.org/10.1097/01.AOG.0000144124.78404.72
2004-11-01
Obstetrics and Gynecology
Abstract:At The American College of Obstetricians and Gynecologists’ 2004 Annual Clinical Meeting, Katie Couric of NBC’s Today Show challenged us to increase the number of women screened for colon cancer. Colorectal cancer currently ranks third among cancer-related deaths in women and takes twice as many lives as ovarian cancer. Although our patients are eager to be screened for ovarian cancer, less than half are screened for colorectal cancer. Ironically, we have reliable techniques to detect early-stage colorectal cancer, which have been proven to reduce mortality; in contrast, diagnosing early-stage ovarian cancer has been an elusive goal. More than 80% of colorectal cancers arise from adenomatous polyps, and the detection and removal of adenomatous polyps has been shown to reduce the incidence and mortality of colorectal carcinoma. Approximately 10% of adenomatous polyps larger than 1 cm will become malignant within 10 years, and the prevalence of colonic polyps increases from approximately 25% at age 50 years, to 50% by age 75. Thus, most organizations, including The American College of Obstetricians and Gynecologists and the American Cancer Society, have issued evidence-based guidelines that recommend screening for colon cancer, beginning at age 50 in average-risk individuals. Unlike other forms of cancer, there are numerous options to screen for colon cancer. The guaiac reaction is the basis of the commonly used fecal occult blood test. Both home and office guaiac testing, with or without rehydration, have pitfalls related to suboptimal sensitivity, specificity, and positive predictive values, as well as poor patient compliance. Recent modifications of this test use an immunochemical reagent that detects only intact human hemoglobin, thereby improving the specificity for lower gastrointestinal bleeding. Meat and other foods, as well as blood from the nose, stomach, or duodenum, do not lead to a positive test. In addition, this test does not require direct handling of stool (a brush can be dipped in the toilet bowl after a bowel movement), which improves patient compliance. Although still not ideal, annual guaiac testing does reduce colon cancer mortality by approximately one third. Sigmoidoscopy and colonoscopy directly visualize colonic tumors, although accuracy depends on the skill of the operator and on the size and location of abnormalities. Flexible sigmoidoscopy is easier, safer, and less costly than colonoscopy, but only visualizes the distal third of the colon, thereby missing all proximal lesions. It has been argued that sigmoidoscopy identifies those patients most likely to benefit from colonoscopy. However, in a large study performed at 13 Veterans Administration medical centers, more than half of the patients with advanced proximal neoplasia had no distal lesions; these cancers would not have been identified if patients had been screened with sigmoidoscopy alone. Colonoscopy is often considered the “gold standard” for colorectal cancer screening. On the other hand, its accuracy is only 90% for large polyps and 75% for polyps under 1 cm. Persistent or recurrent symptoms, therefore, require further testing and follow-up. The double-contrast barium enema is another commonly used, reasonably sensitive test, which also has limitations, especially when used to screen asymptomatic patients. Although barium enema has a lower risk of perforation than colonoscopy, Beth Y. Karlan, MD